Sernova Corp. (TSE:SVA) Director Buys C$24,000.00 in Stock

Sernova Corp. (TSE:SVA) Director Steven Sangha purchased 100,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 6th. The stock was acquired at an average price of C$0.24 per share, for a total transaction of C$24,000.00.

Steven Sangha also recently made the following trade(s):

• On Tuesday, July 30th, Steven Sangha purchased 35,000 shares of Sernova stock. The stock was acquired at an average price of C$0.28 per share, for a total transaction of C$9,625.00.
• On Monday, July 22nd, Steven Sangha purchased 11,000 shares of Sernova stock. The stock was acquired at an average price of C$0.28 per share, for a total transaction of C$3,080.00.
• On Friday, July 19th, Steven Sangha purchased 51,000 shares of Sernova stock. The stock was acquired at an average price of C$0.29 per share, for a total transaction of C$14,790.00.
• On Monday, July 15th, Steven Sangha acquired 40,000 shares of Sernova stock. The stock was bought at an average price of C$0.31 per share, for a total transaction of C$12,400.00.

Sernova Stock Performance

Sernova stock traded down C$0.03 during mid-day trading on Tuesday, hitting C$0.24. The company had a trading volume of 402,348 shares, compared to its average volume of 156,837. The company has a current ratio of 1.20, a quick ratio of 18.11 and a debt-to-equity ratio of 16.55. Sernova Corp. has a 12-month low of C$0.24 and a 12-month high of C$0.91. The company’s fifty day moving average is C$0.32 and its 200-day moving average is C$0.45. The company has a market capitalization of C$72.82 million, a price-to-earnings ratio of -1.85 and a beta of 1.53.

Sernova (TSE:SVA) last released its quarterly earnings data on Friday, June 14th. The company reported C($0.03) EPS for the quarter, hitting the consensus estimate of C($0.03). Equities research analysts predict that Sernova Corp. will post -0.08 EPS for the current year.

Sernova Company Profile

Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection.